March 17 (Reuters) - Indian drugmakers Zydus Lifesciences and Lupin have signed a licensing and supply deal on Tuesday to ...

As part of the deal, Lupin will pay Zydus upfront licensing fees and milestone-based payments linked to predefined targets.

Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to ...

Zydus Lifesciences has partnered with Lupin Limited to co-market its innovative Semaglutide Injection, aimed at adults with type 2 diabetes mellitus ...

Zydus Lifesciences and Lupin have partnered to co-market Semaglutide Injection, a weight-loss medication, in India ...

Under the Licensing and Supply Agreement signed by both companies, Lupin will have semi-exclusive rights to co-market Zydus’ ...

(Fixes formatting in the last bullet) Feb 25 - Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ...

A study claims that high blood pressure can be easily controlled with just two injections a year. (Representational image: www.pexels.com) New Delhi: In the past few years, the number of patients with ...

Semaglutide is a GLP-1 receptor agonist used to treat Type 2 Diabetes and, increasingly, for weight management by helping ...